KRAS and non-small cell lung carcinoma: In examining the preclinical evidence for trial testing combination treatment of NSCLC in which the KRAS mutation was the biomarker,30 SEABED revealed a high proportion of NSCLC subpopulations having the KRAS mutation that are resistant to both selumetinib and docetaxel, suggesting a smaller likelihood of efficacy for the drug combination.